Published in Clin Infect Dis on October 25, 2002
Trends in production, trafficking, and consumption of methamphetamine and cocaine in Mexico. Subst Use Misuse (2006) 4.01
Tuberculosis and illicit drug use: review and update. Clin Infect Dis (2009) 1.76
Tuberculosis transmission and use of methamphetamines in Snohomish County, WA, 1991-2006. Am J Public Health (2010) 1.24
Crack cocaine and infectious tuberculosis. Emerg Infect Dis (2008) 1.07
Stimulant use and progression to AIDS or mortality after the initiation of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2014) 0.81
Pattern of Tobacco Consumption among TB Patients in a Tuberculosis Referral Center. Tanaffos (2011) 0.80
Contingency Management Interventions for HIV, Tuberculosis, and Hepatitis Control Among Individuals With Substance Use Disorders: A Systematized Review. J Subst Abuse Treat (2016) 0.76
Validity of a self-reported history of a positive tuberculin skin test. A prospective study of drug users. J Gen Intern Med (2004) 0.76
Counting the homeless: a previously incalculable tuberculosis risk and its social determinants. Am J Public Health (2013) 0.76
Housing insecurity and lack of public assistance are risk factors for tuberculin skin test conversion among persons who use illicit drugs in New York City. J Addict Med (2009) 0.75
Active and latent tuberculosis among HIV-positive injecting drug users in Indonesia. J Int AIDS Soc (2015) 0.75
Risky and rushed public crack cocaine smoking: the potential for supervised inhalation facilities. BMC Public Health (2016) 0.75
Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med (2002) 5.30
Defining translational research: implications for training. Acad Med (2010) 4.66
Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann Intern Med (2004) 4.38
A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS (2002) 3.41
Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry (2011) 3.15
Human papillomavirus type 16 and immune status in human immunodeficiency virus-seropositive women. J Natl Cancer Inst (2003) 2.81
HIV infection and bone mineral density in middle-aged women. Clin Infect Dis (2006) 2.67
The clonality of Staphylococcus aureus nasal carriage. J Infect Dis (2005) 2.39
Gender differences in factors associated with adherence to antiretroviral therapy. J Gen Intern Med (2004) 2.37
Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis (2005) 2.15
Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women. J Acquir Immune Defic Syndr (2003) 2.11
HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr (2011) 1.97
Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS (2007) 1.95
Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. J Acquir Immune Defic Syndr (2007) 1.82
Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis (2005) 1.80
Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis (2001) 1.79
Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis (2002) 1.73
Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr (2006) 1.73
Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis (2006) 1.72
Longitudinal study of cervical squamous intraepithelial lesions in human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.71
Overweight and human immunodeficiency virus (HIV) progression in women: associations HIV disease progression and changes in body mass index in women in the HIV epidemiology research study cohort. Clin Infect Dis (2003) 1.70
Medical homes: challenges in translating theory into practice. Med Care (2009) 1.69
Home buprenorphine/naloxone induction in primary care. J Gen Intern Med (2008) 1.67
Strains of Staphylococcus aureus obtained from drug-use networks are closely linked. Clin Infect Dis (2002) 1.63
Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol (2005) 1.58
Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis (2003) 1.57
The effect of highly active antiretroviral therapy on human papillomavirus clearance and cervical cytology. Obstet Gynecol (2009) 1.56
Medicaid patients at high risk for frequent hospital admission: real-time identification and remediable risks. J Urban Health (2008) 1.52
Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. J Acquir Immune Defic Syndr (2007) 1.48
Interpreting the association between HIV and bone mineral density. AIDS (2007) 1.43
Continuity of medical care and risk of incarceration in HIV-positive and high-risk HIV-negative women. J Womens Health (Larchmt) (2002) 1.43
Integrating services for injection drug users infected with hepatitis C virus with methadone maintenance treatment: challenges and opportunities. Clin Infect Dis (2005) 1.41
Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. J Subst Abuse Treat (2008) 1.40
HIV mono-infection is associated with FIB-4 - A noninvasive index of liver fibrosis - in women. Clin Infect Dis (2011) 1.37
Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis (2007) 1.37
Prevalence, incidence, and persistence or recurrence of trichomoniasis among human immunodeficiency virus (HIV)-positive women and among HIV-negative women at high risk for HIV infection. Clin Infect Dis (2002) 1.35
Current sexual activity and risky sexual behavior in older men with or at risk for HIV infection. AIDS Educ Prev (2007) 1.33
High-risk human papillomavirus reactivation in human immunodeficiency virus-infected women: risk factors for cervical viral shedding. Obstet Gynecol (2010) 1.31
Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus. Int J Cancer (2006) 1.28
Longitudinal study of mucosal Candida species colonization and candidiasis among human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women. J Infect Dis (2003) 1.28
Menopause symptoms in HIV-infected and drug-using women. Menopause (2005) 1.27
Prevalence of and risk factors for viral infections among human immunodeficiency virus (HIV)-infected and high-risk HIV-uninfected women. J Infect Dis (2003) 1.27
Gender and hospitalization patterns among HIV-infected drug users before and after the availability of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 1.24
Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men. AIDS Patient Care STDS (2007) 1.22
The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone. J Subst Abuse Treat (2005) 1.22
Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis (2005) 1.22
Factors associated with successful referral for clinical care of drug users with chronic hepatitis C who have or are at risk for HIV infection. J Acquir Immune Defic Syndr (2004) 1.21
Rates and risk factors for condition-specific hospitalizations in HIV-infected and uninfected women. J Acquir Immune Defic Syndr (2003) 1.20
Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. Am J Epidemiol (2006) 1.20
The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr (2003) 1.19
Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women. Cancer Epidemiol Biomarkers Prev (2005) 1.17
Characterization of genital human papillomavirus infection in women who have or who are at risk of having HIV infection. Am J Obstet Gynecol (2002) 1.12
Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis (2003) 1.12
Microsocial environmental influences on highly active antiretroviral therapy outcomes among active injection drug users: the role of informal caregiving and household factors. J Acquir Immune Defic Syndr (2007) 1.10
Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone. J Acquir Immune Defic Syndr (2011) 1.09
Improved quality of life for opioid-dependent patients receiving buprenorphine treatment in HIV clinics. J Acquir Immune Defic Syndr (2011) 1.09
Persistence of inconsistent condom use: relation to abuse history and HIV serostatus. AIDS Behav (2004) 1.07
Prospective study of bone mineral density changes in aging men with or at risk for HIV infection. AIDS (2010) 1.06
Modified directly observed therapy (MDOT) for injection drug users with HIV disease. Am J Addict (2002) 1.06
Effects of methadone on QT-interval dispersion. Pharmacotherapy (2005) 1.04
Influence of sex hormones, HIV status, and concomitant sexually transmitted infection on cervicovaginal inflammation. J Infect Dis (2004) 1.04
Unprotected sex among HIV-positive injection drug-using women and their serodiscordant male partners: role of personal and partnership influences. J Acquir Immune Defic Syndr (2006) 1.04
Analysis of a population-based Pneumocystis carinii pneumonia index as an outcome measure of access and quality of care for the treatment of HIV disease. Am J Public Health (2002) 1.04
Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: a cross-sectional survey. Harm Reduct J (2006) 1.04
On-site medical care in methadone maintenance: associations with health care use and expenditures. J Subst Abuse Treat (2006) 1.03
Extended-release naltrexone for treatment of alcohol dependence in primary care. J Subst Abuse Treat (2010) 1.03
Maternal adherence to the zidovudine regimen for HIV-exposed infants to prevent HIV infection: a preliminary study. Pediatrics (2002) 1.03
Gender differences in illicit substance use among middle-aged drug users with or at risk for HIV infection. Clin Infect Dis (2006) 1.02
Validation of the Spanish translation of the Patient Assessment of Chronic Illness Care (PACIC) survey. Prev Chronic Dis (2008) 1.01
Opioid dependence: rationale for and efficacy of existing and new treatments. Clin Infect Dis (2006) 1.00
The impact of methadone induction on cardiac conduction in opiate users. Ann Intern Med (2003) 0.99
Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging. AIDS (2009) 0.99
Mortality rates and causes of death in a cohort of HIV-infected and uninfected women, 1993-1999. J Urban Health (2003) 0.99
Cardiovascular implications of HIV-induced dyslipidemia. Atherosclerosis (2011) 0.98
Differences between Staphylococcus aureus isolates from medical and nonmedical hospital personnel. J Clin Microbiol (2002) 0.98
Estimating the prevalence of illicit opioid use in New York City using multiple data sources. BMC Public Health (2012) 0.96
First do no harm ... Reduction? Ann Intern Med (2009) 0.96
Use of complementary and alternative medicine in inner-city persons with or at risk for HIV infection. AIDS Patient Care STDS (2008) 0.95
Hepatitis C management by addiction medicine physicians: results from a national survey. J Subst Abuse Treat (2007) 0.95
Improving population health in US cities. JAMA (2013) 0.95
Factors associated with frequent utilization of crisis substance use detoxification services. J Addict Dis (2011) 0.95
Factors affecting reproductive hormones in HIV-infected, substance-using middle-aged women. Menopause (2007) 0.94
Clinical and immunologic progression in HIV-infected US women before and after the introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2003) 0.94
Undergraduate medical education in substance abuse: a review of the quality of the literature. Acad Med (2011) 0.93
The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis (2002) 0.93
Mechanisms by which tumor cells and monocytes expressing the angiogenic factor thymidine phosphorylase mediate human endothelial cell migration. Cancer Res (2003) 0.93
The influence of human leukocyte antigen class I alleles and their population frequencies on human immunodeficiency virus type 1 control among African Americans. Hum Immunol (2011) 0.93